Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 20, 2020
Daily News
August 20, 2020
- 4 Add’l Products Recalled over Flawed Testing at Kyowa CritiCare
August 20, 2020
- Japan Discussing Participation in COVAX Pact: Sr. Health Vice Minister
August 20, 2020
- Boehringer’s Ofev Already Hits Japan Peak Sales Outlook, Momentum Likely to Continue with New Indications
August 20, 2020
- Baqsimi’s NHI Tag Doubled on Foreign Price Adjustment, Payer Rep Questions Rule
August 20, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…